4D Molecular Therapeutics (FDMT) Reports $78.1M Q3 Net Loss
Q3 2026 net loss was $78.1M versus $56.9M in Q3 2025. Cash, cash equivalents and marketable securities totaled $375.0M at September 30, 2026, versus $514.0M at December 31, 2025; the company estimates funding into at least the second half of 2028.Material DetailsContext by AI AnalystThe results acc…